Bimal S. Email & Phone Number

Global investment bank that integrates corporate development strategy and execution with capital raising for innovative life science companies.

Publicly traded biopharmaceutical company (NSDQ: ANEB) focused on developing best-in-class therapeutic solutions for substance use disorders

Private-equity backed high-growth healthcare company focused in treatments for central nervous system disorders. Currently commercializing two approved products. Company previously also owned a contract development and manufacturing organization.Spearheaded corporate and business development, investor outreach, financial planning and analysis, accounting, tax, and information technology. Recruited by and reported to CEO; managed 4 direct reports and 14 overall members.• Financial and strategic achievementso Closed $100M equity investment from third-party investor. o Spun off contract development / manufacturing business and sold portion of it to third-party investor.o Managed critical relationship with debt provider including rolling over financing after business split.o Drove processes to proactively engage top-tier investment banking advisers.o Developed strategy, timing and pathway for future capital raises.• Other achievementso Improved working capital through negotiations with vendors and attention to cash outflow drivers.o Led build-out of accounting and IT functions, including transition to new ERP environment.o Closed out-licensing transaction for select Asian countries for upfront and milestone payments.o Collaborated in defining career development options for colleagues that enhanced corporate culture.

Wholly-owned subsidiary of Sumitomo Dainippon Pharma, top 10 publicly traded Japanese pharma company. Sumitovant is the parent company to 5 biopharma companies (4 wholly-owned and one a majority-owned publicly traded company) across various therapeutic categories and is primary growth driver of Sumitomo Dainippon Pharma.Oversaw financial planning and analysis function, including long-range forecast, budgeting and variance analysis. Managed 2 direct reports and 5 overall team members. Developed strategy for accessing external sources of capital for portfolio companies. Provided oversight to corporate strategy function including long-range strategic plan and tactical implementation. Provided feedback on investor relations activities as warranted.• Monitored performance and activities of portfolio companies; evaluated and recommended actions on key decisions, which contributed to strong commercial launch performance.• Managed complexities created by multinational structure and multiple tax and accounting rules. • Selected to lead enterprise risk management evaluation. • Managed critical strategic merger and acquisition transaction opportunities including acquisitions of minority interests in subsidiaries.

Publicly traded biopharmaceutical company focused in treatments for hematological and solid tumor oncology indications. Company developed, obtained approval, launched and commercialized multiple products, all of which were obtained through business development.Member of management team reporting to CEO at critical times, served in various key leadership roles. In addition to functional leadership responsibilities, actively shaped overall company strategy and contributed to operational performance. Core activities included cultivating and sustaining rich deal network, leading due diligence activities in both buy- and sell-side situations, overseeing valuations and other data-driven analyses, negotiating terms and definitive legal documentation, reviewing transactions with management and board, and managing alliances post-closing.• Led cross-functional team to identify and assess over 100+ strategic opportunities per year on global basis, including mergers, acquisitions, out- and in-licensing, and other partnerships. • Provided competitive intelligence insight into developmental decision-making that contributed to go/no-go investment decisions.• Executed ~20 transactions across broad variety of transaction types (in-license, out-license, acquisition, asset purchase and asset sale), stages of development, and molecule type (small molecules both oral and injectable and biologics both proteins and antibodies).

Irvine, Ca

Led select financial activities including investor relations, financial planning and analysis, treasury, and capital-raising activities. Collaborated as needed regarding special projects and issues for accounting, audits and SEC filings.• Managed investor and public relations, crafted company's messaging for both buy-side and sell-side investors, presented at major healthcare investment banking conferences, and executed initiatives to boost overall interest.• Crafted roadmap for business development activities, including strategy, criteria and sourcing approach, leading to significant increase in deals reviewed and executed transactions.

Irvine, California, United States

Served on consulting basis in senior finance and BD capacity as a planned transition to a full-time role.

Diversified global private equity firm focused primarily on growth investments.Worked on venture capital, growth equity, PIPE and leveraged buy-out investments.

World’s first biotechnology company known for its pioneering research that led to breakthrough treatments for many diseases.Worked in Commercial Assessments team (part of Market Development group) and also in business development.

Diversified global private equity and venture capital firm.Worked on venture capital investments in life science and medical device companies.

Leading global investment banking, securities and investment management firm that provides a wide range of financial services.Worked on equity, debt, M&A, and strategic alliance transactions

Master'S, Business Administration

Master Of Arts, International Policy Studies

Ba, Economics